Acknowledgement
This study was supported by National Evidence-based Healthcare Collaborating Agency (NR20-001; NR21-001).
References
- Yoo SL, Kim DJ, Lee SM, Kang WG, Kim SY, Lee JH, et al. Improving patient access to new drugs in South Korea: evaluation of the national drug formulary system. Int J Environ Res Public Health 2019;16(2):288. https://doi.org/10.3390/ijerph16020288
- Bae EY, Hong J, Bae S, Hahn S, An H, Hwang EJ, et al. Korean guidelines for pharmacoeconomic evaluations: updates in the third version. Appl Health Econ Health Policy 2022;20(4):467-477. https://doi.org/10.1007/s40258-022-00721-4
- Zhao Y, Feng HM, Qu J, Luo X, Ma WJ, Tian JH. A systematic review of pharmacoeconomic guidelines. J Med Econ 2018; 21(1):85-96. https://doi.org/10.1080/13696998.2017.1387118
- Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine. 2nd ed. Oxford: Oxford University Press; 2017, p. 82-86.
- Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996, p. 68, 89-94, 178,-183, 190-208.
- Health Insurance Review and Assessment Service (HIRA). Guide-lines for economic evaluation of pharmaceuticals; 2021 [cited 2021 Mar 15]. Available from: https://www.hira.or.kr/ebooksc/ebook_630/ebook_630_202103150917443810.pdf (Korean).
- Oliver A. A normative perspective on discounting health outcomes. J Health Serv Res Policy 2013;18(3):186-189. https://doi.org/10.1177/1355819613485671
- Paulden M, O'Mahony JF, McCabe C. Discounting the recommendations of the second panel on cost-effectiveness in health and medicine. Pharmacoeconomics 2017;35(1):5-13. https://doi.org/10.1007/s40273-016-0482-0
- Lee J, Jeong D, Cho M, Kim Y. A study on revision and supplementation of general guidelines for conducting preliminary feasibility studies for public corporations and quasi-governmental institutions. 2nd ed. Sejong: KDI Public Investment Management Center; 2018, p. 190-192 (Korean).
- Kim YE, Jung YS, Ock M, Yoon SJ. A review of the types and characteristics of healthy life expectancy and methodological issues. J Prev Med Public Health 2022;55(1):1-9. https://doi.org/10.3961/jpmph.21.580
- Lee YK, Nam HS, Chuang LH, Kim KY, Yang HK, Kwon IS, et al. South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health 2009;12(8):1187-1193. https://doi.org/10.1111/j.1524-4733.2009.00579.x
- Jo MW, Ahn JH. A study on the estimation of the utility of EQ5D-5L health status in adults in Korea. Seoul: National Evidencebased Healthcare Collaborating Agency; 2013, p. 63 (Korean).
- Kim SH, Ahn J, Ock M, Shin S, Park J, Luo N, et al. The EQ-5D-5L valuation study in Korea. Qual Life Res 2016;25(7):1845-1852. https://doi.org/10.1007/s11136-015-1205-2
- Jo MW. A study on the valuation of Korean health-related measurement tools (HINT-8) for quality of life. Cheongju: Korea Disease Control and Prevention Agency; 2017, p. 91 (Korean).
- Rascati KL. Essentials of pharmacoeconomics. Philadelphia: Lippincott Williams & Wilkins; 2009, p. 9-23.
- Yuasa A, Yonemoto N, LoPresti M, Ikeda S. Use of productivity loss/gain in cost-effectiveness analyses for drugs: a systematic review. Pharmacoeconomics 2021;39(1):81-97. https://doi.org/10.1007/s40273-020-00986-4
- Kim Y, Kim YW, Choi IJ, Cho JY, Kim JH, Kwon JW, et al. Cost comparison between surgical treatments and endoscopic submucosal dissection in patients with early gastric cancer in Korea. Gut Liver 2015;9(2):174-180. https://doi.org/10.5009/gnl13299
- Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 2006;24(9): 869-890. https://doi.org/10.2165/00019053-200624090-00005
- Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics 2016;34(1):43-58. https://doi.org/10.1007/s40273-015-0325-4
- Park BJ, Heo DS, Lee SM, Ahn HS, Ji SH, Bae EY, et al. Evidencebased healthcare. Seoul: Park Youngsa Publishing; 2018, p. 270, 274-276, 278 (Korean).
- Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011;29(5):371-386. https://doi.org/10.2165/11539960-000000000-00000
- Woods BS, Sideris E, Palmer SJ, Latimer N, Soares MF. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review; 2017 [cited 2022 Sep 10]. Available from: https://www.sheffield.ac.uk/nice-dsu/tsds/partitioned-survival-analysis.
- Bullement A, Cranmer HL, Shields GE. A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Appl Health Econ Health Policy 2019;17(6): 771-780. https://doi.org/10.1007/s40258-019-00513-3
- Park BJ, Heo DS, Ahn HS, Lee SM, Yoon YH, Kim SY, et al. Evidence-based healthcare, Seoul: Korea Medicine; 2009, p. 207 (Korean).
- Ahn JH, Kim YH, Shin SJ, Park SY, Song HJ, Park JY, et al. A methodological study of Korean healthcare decision-making suitable for evidence-based treatment. Seoul: National Evidencebased Healthcare Collaborating Agency; 2010, p. 125-160 (Korean).
- Bae EY. What should the cost-effectiveness threshold reflect? Korean J Health Econ Policy 2018;24(2):83-106 (Korean).
- Ahn JH, Kim YH, Shin SJ, Park JY. A joint Asian study on costeffectiveness in health care decision making. Seoul: National Evidence-based Healthcare Collaborating Agency; 2012, p. 17-20 (Korean).
- Song HJ, Lee EK. Evaluation of willingness to pay per qualityadjusted life year for a cure: a contingent valuation method using a scenario-based survey. Medicine (Baltimore) 2018; 97(38):e12453. https://doi.org/10.1097/MD.0000000000012453
- Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 2012; 32(5):722-732. https://doi.org/10.1177/0272989X12458348